A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION)

drug protocol number
D5180C00018
drug sponsor
AstraZeneca
drug study
Tezepelumab
drug trial site
KAUH-J
drug status
Ongoing
drug phase